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Abstract
Background: Morphologically similar cancers display heterogeneous patterns of molecular aberrations and follow
substantially different clinical courses. This diversity has become the basis for the definition of molecular phenotypes, with
significant implications for therapy. Microarray or proteomic expression profiling is conventionally employed to identify
disease-associated genes, however, traditional approaches for the analysis of profiling experiments may miss molecular
aberrations which define biologically relevant subtypes.
Methodology/Principal Findings: Here we present Messina, a method that can identify those genes that only sometimes
show aberrant expression in cancer. We demonstrate with simulated data that Messina is highly sensitive and specific when
used to identify genes which are aberrantly expressed in only a proportion of cancers, and compare Messina to
contemporary analysis techniques. We illustrate Messina by using it to detect the aberrant expression of a gene that may
play an important role in pancreatic cancer.
Conclusions/Significance: Messina allows the detection of genes with profiles typical of markers of molecular subtype, and
complements existing methods to assist the identification of such markers. Messina is applicable to any global expression
profiling data, and to allow its easy application has been packaged into a freely-available stand-alone software package.
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Introduction
Key molecular events in the development of disease are usually
not ubiquitous, leading to instances of disease with similar
morphological characteristics often having substantially disparate
molecular phenotypes. This heterogeneity, far from being an
unimportant epiphenomenon of disease development, has proven
important in therapy: major advances in cancer therapeutics and
patient outcomes have been achieved through the study and
targeting of specific molecules and molecular mechanisms such as
the estrogen receptor, and HER2/neu, aberrant expression of
which occurs in approximately 30% and 25% of breast cancers,
respectively [1,2,3]. Thus inconsistent molecular aberrations,
which do not occur in every case of a disease, are biologically
and clinically relevant and have proven useful in the development
of effective therapies.
Traditional analysis methods for global gene expression data are
poorly suited for the identification of genes that are aberrantly
expressed at low frequency, and will fail to find genes that show
aberrant expression in only a small subset of samples. This
limitation in conventional techniques is gaining recognition, and
new analyses of cancer datasets searching for genes with low
frequency aberrant expression have produced novel insights into
disease [4,5].
Here we present Messina, a novel technique that identifies genes
with lower frequencies of aberrant expression in disease. In
contrast to currently available outlier detection methods (e.g.
[4,6,7]), Messina can smoothly vary between identifying consistent
differences, as in traditional approaches, to selecting the low
frequency outliers found by current outlier detection techniques.
This flexibility allows prior biological knowledge about the
expected frequency of aberrant gene expression to inform the
analysis, and enables the user to more specifically identify the
genes of interest. Messina has its roots in machine learning theory,
and its results can be directly used to implement robust single-gene
classifiers separating case and control sample groups with user-
supplied minimum sensitivity and specificity. In our work this has
been useful in identifying lead target proteins for the development
of radioactive tracers for disease diagnosis and localisation, but is
generally applicable to any diagnostic problem for which the
number of genes that can be measured is strictly limited. This
paper describes the implementation, performance and validation
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demonstrates its utility in the detection of inconsistent differential
expression in a case-control setting.
Results
Messina is an algorithm for constructing classifiers capable of
separating two sample groups (eg. cancer and normal tissue) on the
basis of the expression level of a single gene. Classifiers (and thus
genes) which can be used to separate the two sample groups are
reported to the user as the final result of the algorithm.
Although Messina is fundamentally a classifier, its primary use is
to identify genes with low frequency aberrant expression, such as
markers of molecular subtype, thus complementing existing
approaches that identify genes that show either consistent or
outlier profiles. Messina identifies genes with low frequency
aberrant expression by allowing the analyst to specify minimum
sensitivity (the fraction of case samples that are placed into the case
group by the classifier) and specificity (the fraction of control
samples that are classified as being in the control group)
constraints that classifiers must satisfy. The sensitivity can be
considered to reflect the proportion of case samples with ‘case-like’
expression levels, and the specificity the proportion of control
samples with ‘control-like’ expression. By modifying these two
inputs the analyst can tune Messina to identify genes with
particular profiles of expression across the spectrum from highly
consistent differences (sensitivity and specificity both high), to
genes detected by current outlier techniques (sensitivity low,
specificity high). This link between classifier performance and low
frequency aberrant expression is further developed in Methods S1.
Messina selectively identifies genes of interest
We evaluated Messina’s ability to detect genes that display
aberrant expression in at least a user-defined proportion of samples
using a series of simulation experiments which model genes with
known frequencies of differential expression. These experiments
examined how accurately Messina identified onlythose genes which
satisfied its input performance constraints across a range of
simulated experimental conditions. The selectivity of a simple t test
was also examined to contrast its performance with Messina.
We generated simulated case-control expression data that
spanned a range of sample sizes, differential expression magnitude
(the difference between case and control sample distribution
means), and differential expression degree. We defined differential
expression degree as the fraction of simulated case samples which
were drawn from the case distribution rather than the control
distribution; this was varied in order to examine performance
under conditions of inconsistent differential expression. Conven-
tional analyses assume degree is equal to 1; values lower than 1
indicate that some case samples display control-like expression
levels, and are indicative of low frequency aberrant expression.
Under the conditions of the simulation, the simulated gene’s
differential expression degree was equal to the theoretical optimal
sensitivity of a classifier based upon that gene. Therefore, an ideal
gene detection response would be zero detection if the simulated
gene’s degree was less than the supplied sensitivity cutoff, and full
detection otherwise.
In all sample size scenarios, Messina detected only those genes
with degrees of differential expression near to or exceeding its
supplied sensitivity threshold (Figure 1). For genes with a small
magnitude of differential expression (one log2 unit), Messina’s
detection efficiency reached a plateau at approximately 80%
(Figure 1b,d), however for genes with a four-fold change and
above Messina’s detection efficiency rapidly approached 100%
with increasing degree of differential expression, even in the case
of only five samples per group (Figure 1a,c).
To illustrate the performance of a simple conventional analysis
method, we applied a t test to the simulated data. The t test
displayed a rapid increase in detection performance with increasing
degree of differential expression, with the critical degree at which
detection became likely varying with the sample size, magnitude of
differential expression, and supplied test size (Figure 2). Notably,
manipulation of the one free parameter in the t test (the test size) did
not effectively change the degree of differential expression required
for consistent detection (data not shown).
In contrast to the t test, Messina could be tuned to detect low
frequency aberrant expression. However, it was important to
verify that this improved flexibility did not come at the expense of
specificity, and that Messina was still strongly selective against
genes that did not satisfy its supplied criteria. Messina’s specificity
naturally increases as the minimum degree of differential
expression required for detection is increased. In simulations of
data with 20 samples per group, Messina’s false discovery rate
(FDR), defined as the fraction of detected genes with less than the
minimum required simulation frequency of differential expression,
was 2.26%. For the more demanding case of only five samples per
group, Messina’s FDR was 8.17% at the very liberal 50%
sensitivity cutoff, and only 1.09% at the more stringent 90% cutoff.
In all cases, even under demanding conditions of a very liberal
minimum classifier sensitivity cutoff and small sample size,
Messina effectively controlled the false discovery rate.
Illustration of Messina vs limma
Simulation studies indicated that Messina reliably detected
inconsistent differential expression in complex microarray datasets
with few samples per group. In order to demonstrate its relevance
to contemporary biological problems, we compared the algorithm
to limma, an established conventional analysis platform, in the
analysis of a representative experiment. Both Messina and limma
were used to analyse a previously-published microarray data set
[8] comparing human pancreatic cancer samples to normal
pancreas.
The results of the Messina and limma analyses were broadly
concordant (Figure 3a). Of 44,928 probesets in total, 42,405
(94.4%) were considered not differentially expressed by either
technique, while 837 (1.9%) were considered differentially
expressed by both techniques. The techniques disagreed for
1,686 (3.8%) probesets, 809 of which were considered differentially
expressed by Messina alone, and 877 of which were only
considered differentially expressed by limma.
To demonstrate the differences between the analysis techniques
we selected six illustrative cases of the 1,686 discordant probesets
(Figure 3b). All three Messina-selected probesets displayed a high
intra-group variability, with one to two cancer samples exhibiting
an expression level close to that of normal tissue (Figure 3b, panels
x–z). Nonetheless, all three probesets could form the basis of
single-gene classifiers with wide classifier margins. Conversely, two
of the probesets selected by limma, but considered unattractive by
Messina, show quite low intra-group variability and a small mean
difference (Figure 3b, panels v, w). A third probeset selected by
limma was rejected outright by Messina (Figure 3b, panel u).
Although this probeset could be used to construct a classifier with a
reasonably large margin, the presence of a sample of normal tissue
with expression close to the cancer group drastically reduces the
specificity of a classifier based upon this probeset. As Messina was
supplied a minimum specificity requirement of 90% when these
data were analysed, and this probeset could not satisfy this
condition, it was rejected by Messina.
The Messina Algorithm
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differentially-expressed by Messina, but not by limma (Figure 3b,
panel y), and thus it was of interest to determine if S100A2 was
differentially-expressed in a larger cohort, using a different assay to
validate Messina’s findings. S100A2 protein levels in a pancreatic
cancer cohort of 115 patients [8] were measured by IHC. Scoring
of staining intensity and percentage of staining cells revealed
moderate or high S100A2 expression in 29 samples (25.2%), of
which 13 samples (11.3%) displayed very strong staining, in
agreement with the Messina results. High expression of S100A2 in
this cohort was significantly associated with a poor prognosis (data
not shown).
Discussion
Genes that display low frequencies of differential expression in
disease have often been neglected by high throughput studies
despite their central role in the definition of molecular subtypes.
Traditional analysis methods typically ignore such genes, and new
techniques capable of identifying genes with low frequency
aberrant expression have produced promising results [4,5].
However, these outlier detection techniques offer little flexibility
in the types of gene profiles selected, selecting only genes
displaying high magnitude aberrant expression at a very low
frequency. Messina is a flexible method that is ideally suited for the
analysis of small datasets, and bridges the gap between traditional
analysis techniques and newer outlier detection approaches.
Messina’s flexibility allows the user to input prior biological
knowledge about the expected patterns of aberrant expression to
inform the analysis, an advantage in heterogeneous diseases such
as cancer.
Messina naturally detects low-frequency differential expression,
an area upon which conventional analysis techniques do not
specifically focus. When compared to the commonly-used t test,
Messina was superior at identifying genes with low frequency
differential expression (Figures 1,2), especially with small sample
sizes, and maintained a low FDR under all conditions. Many more
sophisticated analysis methods are refinements of the t test and
Figure 1. Messina detection performance. Each plot displays the probability that a gene will be detected by Messina, as a function of the gene’s
degree of differential expression, for three different sensitivity cutoffs: 50% (orange), 70% (green) and 90% (blue). Under these simulation conditions,
an ideal response is zero detection for degrees under the sensitivity cutoff, and complete detection for degrees at or above the sensitivity cutoff. In all
cases, Messina’s specificity cutoff was set to 90%.
doi:10.1371/journal.pone.0005337.g001
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frequency aberrant expression.
When used for its designed purpose, Messina performed
favourably when compared to a popular and highly powerful
analysis platform, limma. The results of Messina and limma were
broadly concordant (Figure 3); however their disparate results
highlight their different application. Limma very sensitively detects
consistent differences in expression, even when these differences
are subtle, but permits little flexibility in the types of differential
expression profiles found. Messina detects both consistent and
inconsistent differences in expression and grants the experimenter
great flexibility, but favours large margins. These approaches are
complementary: limma and other conventional microarray
analyses are appropriate to detect genes that are differentially
expressed in close to every single sample of a group, whereas
Messina is optimised to detect differences between groups even if
the differential expression is present at a low frequency. Although
Messina cannot analyse the complex experimental designs handled
by limma, for a simple case-control type analysis it serves as a
useful adjunct method.
The key strength of Messina is that the method provides a
mechanism by which the user can control the types of gene profiles
selected, and the performance and robustness of the classifiers that
are based upon the selected genes. Messina accepts from the user
the minimum sensitivity and specificity values that all classifiers
(equivalently, genes) identified must satisfy, and therefore allows
the experimenter to flexibly reduce the stringency of the gene
selection process. The benefit of allowing more lenient cutoffs is
twofold: in a classification context it permits the discovery of more
robust classifiers, and in a gene discovery context it enables the
detection of genes with inconsistent aberrant expression. If high
classifier robustness or the detection of genes with inconsistent
expression are a main goal, the sensitivity cutoff may be relaxed,
trading classifier performance for improved resistance to noise,
and a low false positive rate for improved detection of inconsistent
aberrant expression. Should the analysis require it, the specificity
cutoff can also be reduced, with a similar attendant trade-off. In
simulations Messina faithfully matched the supplied constraints
across a wide range of restrictions and gene expression scenarios,
permitting the researcher to flexibly experiment with performance
requirements with confidence that these constraints will be
respected by the identified genes and classifiers. However, as the
constraints are relaxed beyond a point the genes thus found will be
progressively less likely to be biologically relevant; this point will
vary with the particulars of the experiment and the downstream
application of the identified genes, and defines Messina’s lowest
practical sensitivity and specificity thresholds. To our knowledge, no
other analysis technique allows this control over the types of
differential expression detected, nor the performance of classifiers
thus generated.
Messina’s ability to detect genes with inconsistent aberrant
expression was demonstrated using immunohistochemistry, by
which S100A2 was found overexpressed in 25% of samples. The
expression pattern of S100A2 (Figure 3a, point y) is typical of
markers of molecular subtype; such patterns are penalised by many
conventional techniques due to their high intra-group variance.
Whereas conventional analysis techniques promise great
sensitivity in detecting genes with subtle but consistent changes
in expression, Messina offers the opportunity to identify those with
inconsistent differences. Accumulated knowledge about disease
biology indicates that both types of genes are likely to be
important, and by using a combined approach the researcher is
offered a broader range of analyses to guide further work.
Messina’s flexibility is unique in the emerging field of low
frequency differential expression analysis, and this feature makes
Messina a natural companion to traditional methods of analysis,
being able to detect many different types of expression profiles
depending on its input parameters. The Messina software is free,
and includes a user-friendly graphical interface for use by
biologists.
Methods
Threshold classifiers
The classifiers trained by Messina decide the class of an
unknown sample by comparing the expression of a single gene in
Figure 2. t test detection performance. As per Figure 1, each plot displays the probability of a gene being detected as differentially-expressed as
a function of its degree of differential expression. Line types represent three different differential expression magnitudes: 2-fold (dotted line), 4-fold
(dashed line) and 16-fold (solid line). A gene was defined as detected if it was assigned a Benjamini-Hochberg corrected P-value for the difference in
group means of less than 0.01.
doi:10.1371/journal.pone.0005337.g002
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sample exceeds the threshold value, the sample is assigned one
class, and the remaining class otherwise. Threshold classifiers are
completely specified by the classifier’s threshold value, and its
direction, the latter being the class to which samples with
expression exceeding the threshold are assigned.
Core training algorithm
Given the classifier direction and a set of sample expression
values and associated classes, classifier sensitivity and specificity (as
evaluated on the training data) are monotonic functions of the
classifier threshold value. The (possibly empty) set of threshold
values for which the sensitivity and specificity both satisfy the
experimenter-supplied constraints is termed the feasible region for a
given gene and classifier direction. Following the reasoning
underlying the Support Vector Machine [9], the final threshold
is selected as the midpoint of the feasible region, resulting in a
maximum margin of safety before either of the classifier
constraints is violated. This margin is employed as a measure of
classifier robustness to noise: classifiers with larger margins are
supposed to be more resistant to measurement error or
peculiarities of the training set. Messina’s training algorithm is
illustrated in Figure S1 and described in more exhaustive detail in
Methods S2, where the close link between Messina and empirical
cumulative distribution functions is also developed.
Messina implementation
For each gene, Messina’s core training algorithm determines the
feasible region for both classifier directions. In the case of both
directions yielding a feasible region, the one with the largest
margin is selected. In the case of genes that do not yield a feasible
region for either classifier direction, the training algorithm
produces a zero-rule classifier that randomly produces class labels
with frequencies equal to the training set class frequencies. During
cross-validation (CV), this naturally penalises genes which cannot
consistently be used to produce acceptable classifiers.
Messina’s core training algorithm is wrapped in a CV loop that
employs independently-sampled data set splits [10]. The mean CV
performance is compared to the performance constraints, and if
these CV performance estimates satisfy the constraints, the
classifier is trained on the full data set, and the full classifier
parameters and CV performance reported to the user.
The overall steps of the Messina procedure are presented in
pseudo-code form in Figure S2.
Messina software
Software that implements the Messina algorithm is freely-
available at http://www.garvan.unsw.edu.au/public/mpinese/
messina.
Detection performance simulation study
In order to test Messina’s detection performance, we produced a
series of simulated microarray datasets with known differential
expression using data from a previously-published study [8]. This
data set included six normal human pancreas samples hybridised
to Affymetrix HG-U133A microarrays. To characterise the data
for subsequent synthesis, array pre-processing was performed
using RMA [11], and for each probeset a maximum-likelihood
lognormal distribution was fit to the six normal sample RMA
expression measures.
The synthetic datasets were generated by drawing simulated
case and control samples from lognormal distributions: control
samples from a distribution with a lower mean, and case samples
from either the control distribution or a case distribution with a
higher mean. The proportion of case samples drawn from the case
distribution was varied to simulate a range of differential
expression types from highly consistent (high proportion) to outlier
(low proportion). Full details of the generation procedure follow.
For each synthetic probeset, n simulated control samples and n
simulated case samples were generated by random sampling from
two lognormal distributions. The mean of the lognormal
distribution of the n control samples, and m of the case samples,
was ln t; the mean of the lognormal distribution of the remaining
n–m case samples was ln (t + d), with d representing a gene’s
magnitude of differential expression. In the experiments, t M{4, 6,
8, 10}, d M {1, 2, 4}, m M{0, …, n}, and n M{5, 10, 20}. m
represents the number of case samples that exhibit a control-like
distribution; as m approaches n the proportion of simulated case
samples that are generated from the case distribution decreases.
To simulate the heteroskedascity common in array data, standard
deviations of the simulated probeset lognormal distributions were
generated empirically by random sampling from the standard
deviations of the lognormal fits to the array data. This sampling
was performed independently for the samples with mean ln t and
the samples with mean ln (t + d); sampling was from within those
fitted probesets that had a fitted mean expression value within 0.1
percentiles of the simulated probeset mean. A simulated gene’s
degree of differential expression was defined as d=12m/n. 100
simulated probesets were generated for each combination of t, d,
and n, yielding 45,600 simulated probesets in total.
The Messina analysis and a two-sample t test procedure were
applied to the simulated data in order to evaluate the detection
performance of the two methods. Messina was run upon the data
three times, with sensitivity cutoffs of 50%, 70% and 90%; all runs
employed a specificity cutoff of 90%, 60 CV iterations, and a
training set size of 90% of the full data. A probeset was considered
detected by Messina if its CV sensitivity and specificity were both
at least as high as the supplied cutoff values. Welch’s two-sample t
test was also applied to the data, testing for each probeset the null
hypothesis of no difference between the case and control means. A
probeset was considered detected by the t test if its Benjamini-
Hochberg corrected [12] P-value was less than 0.01. Detection
probability was defined as the proportion of probesets that were
detected by an analysis method for fixed values of d and n, as a
function of the degree of differential expression.
Application to pancreatic cancer data
In order to contrast Messina with conventional techniques, we
applied the algorithm to a small pancreatic cancer data set, and
Figure 3. Comparison of Messina and limma results. (a) Log10-transformed limma P-values are displayed on the horizontal axis; a vertical line at
22 units denotes the P,0.01 cutoff value. Ranks of Messina-assigned margins occupy the vertical axis, with larger margins being assigned smaller
ranks; a horizontal line at rank 1,646 denotes the margin .1 cutoff value. Limma P-values for probesets rejected outright by Messina (ie. no threshold
could satisfy the input performance requirements) are displayed above the horizontal line at rank 15,898; the vertical position for these Messina-
rejected probesets has been jittered for display purposes only. Probesets selected by both methods are plotted as filled black circles, all other
probesets are plotted as black dots. Six discordant probesets that were selected for closer examination are highlighted by open circles. (b) Expression
profiles of selected discordant probesets. Grey and black bars represent normal and cancer samples, respectively. For the probesets selected by
Messina (panels x2z), the relevant feasible region and margin size are marked.
doi:10.1371/journal.pone.0005337.g003
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analysis technique [13] implemented in the package limma [14]. A
subset of a previously-published microarray study [8] was used;
this subset featured data from six bulk pancreatic adenocarcino-
mas and six unmatched bulk normal pancreata, hybridised to
Affymetrix U133 A and B arrays. Array pre-processing was
performed using RMA [11].
The array data were analysed separately using Messina and
limma. In the Messina analysis genes were selected if their CV
performance passed the supplied performance thresholds of 50%
sensitivity and 90% specificity and they had a classifier margin of
at least one log2 unit; in the limma analysis genes were labelled as
differentially expressed if they were assigned a Benjamini-Yekutieli
(BY) corrected [15] P value for no difference between cancer and
normal mean expression of less than 0.01. To facilitate comparison
between Messina and limma results, the rank of Messina’s
reported probeset classifier margin (a measure of the robustness
of the trained classifier) was compared to the log10-transformed
BY-corrected [15] P value reported by limma.
Immunohistochemistry
To validate Messina’s results, we measured expression of
S100A2 protein by immunohistochemistry upon a separate patient
cohort from that used in the microarray data [8]. Tissue
microarray sections were dewaxed in xylene and rehydrated, then
unmasked in retrieval solution (S2367, DAKO) at 121uCi na
pressure cooker for 5 minutes. Slides were blocked with 3% H2O2
in methanol and incubated with 1:50 mouse antibody to S100A2
(DAK-2100A2/1, NeoMarkers) for 60 minutes. Detection was
performed using Envision+ anti mouse (DAKO) with a 3,39-
diaminobenzidine substrate and slides were counterstained with
hematoxylin. All slides were double scored by independent
observers including a histopathologist.
Supporting Information
Methods S1 Informal development of the reasoning underlying
the core of the Messina algorithm.
Found at: doi:10.1371/journal.pone.0005337.s001 (0.03 MB
DOC)
Methods S2 Formal development of the link between the
Messina algorithm and inverse eCDF estimation.
Found at: doi:10.1371/journal.pone.0005337.s002 (0.06 MB
DOC)
Figure S1 Illustration of the Messina training algorithm. The
main plot shows the classifier sensitivity or specificity as a function
of the threshold, for the classifier direction in which expression less
than the threshold value is associated with control samples.
Sample expression (n=6 per group) is depicted by boxes beneath
the main plot; empty boxes represent control samples and filled
boxes case samples. The algorithm’s supplied performance limits
in this example (sensitivity $ 0.6, specificity $ 0.9) are represented
by horizontal dotted lines, and when combined with the sensitivity
and specificity curves define threshold values that produce
classifiers with acceptable sensitivity and specificity, respectively.
The range of possible thresholds in which both sensitivity and
specificity satisfy the supplied constraints is denoted the feasible
region. Messina selects a threshold in the centre of this feasible
region, and defines the classifier margin as the width of the feasible
region.
Found at: doi:10.1371/journal.pone.0005337.s003 (0.82 MB TIF)
Figure S2 The Messina algorithm pseudo-code.
Found at: doi:10.1371/journal.pone.0005337.s004 (0.03 MB
DOC)
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